Evidence map›Paper›PMID 40457435›Full record

ArticleStem cell research & therapy2025

Restoration of NOX4 signalling reverses endothelial colony-forming cell angiogenic dysfunction associated with experimental and clinical diabetes.

Karla M O'Neill, Kevin S Edgar, Shun Hay Pun, David C Campbell, Tinrui Toh, Xin N Wong, Bianca Botezatu, Jyoti Kandel, Una McCoy, Jennifer Nicell and 17 more

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Karla M O'NeillWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Kevin S EdgarWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Shun Hay PunWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
David C CampbellWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Tinrui TohWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Xin N WongWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Bianca BotezatuWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Jyoti KandelWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Una McCoyWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Jennifer NicellWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Catherine McClintockWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Kiran J McLoughlinWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Yuxin WuWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Vinuthna Vani MadishettiWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Arya MoezWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Mohammed AlsaggafWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Eleanor K GillWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Rawan A AbudaloWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Christina L O'NeillWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Edoardo PedriniWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Jasenka Guduric-FuchsWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Coy BrunssenDivision of Vascular Endothelium and Microcirculation, Dresden University of Technology, Dresden, Germany.
Henning MorawietzDivision of Vascular Endothelium and Microcirculation, Dresden University of Technology, Dresden, Germany.
Philip D DunnePatrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
Chris J WatsonWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Reinhold J MedinaWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
David J GrieveWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK. d.grieve@qub.ac.uk.ORCID http://orcid.org/0000-0003-3458-8829

Funding

British Heart Foundation PG/14/78/3109British Heart Foundation PG/19/61/34586British Heart Foundation PG/21/10689Deutsche Forschungsgemeinschaft 470814312Deutsche Forschungsgemeinschaft IRTG 2251/2Deutsche Forschungsgemeinschaft MO 1695/4-1Deutsche Forschungsgemeinschaft MO 1695/5-1Diabetes UK 20/0006162Medical Research Council MR/S036695/1Society of The Friendly Sons and Daughters of Saint Patrick Ref. USI 158
6 · The paper itself

Abstract

backgroundProgenitor endothelial colony forming cells (ECFCs) are critical for vascular homeostasis and hold therapeutic potential for ischaemic cardiovascular disease (CVD). As angiogenic capacity and efficacy within diseased tissues is particularly impacted in diabetic patients, who show high incidence of ischaemic CVD, targeting of critical ECFC pathways in this setting represents an innovative focus towards enhancing intrinsic vasoreparative function. We previously reported that NADPH oxidase 4 (NOX4)-derived reactive oxygen species promote cord blood-derived ECFC (CB-ECFC) pro-angiogenic response, whilst NOX4 overexpression (OE) enhances revascularisation capacity. Here, we aimed to investigate specific influence of NOX4-dependent signalling on CB-ECFC angiogenic dysfunction observed upon exposure to both experimental and clinical diabetes to define whether NOX4 may represent a viable therapeutic target in this context.

methodsCB-ECFCs were cultured in high glucose (D-glucose, 25 mmol/L) or control media (5 mmol/L) ± phorbol 12-myristate 13- acetate (PMA, 500 nmol/L) for 72 h with assessment of migratory/tubulogenic capacity and NOX4 mRNA expression (qRT-PCR). Detailed analysis of angiogenic function and signalling (Western blot, RNA sequencing) was performed in CB-ECFCs isolated from donors with gestational diabetes prior to NOX4 plasmid OE to define rescue potential and key mechanistic pathways (network analysis, proteome profiling). Statistical significance was determined using one-way ANOVA with Bonferroni post-host testing or paired/unpaired Student's t-test, as appropriate.

resultsPMA-stimulated CB-ECFC migration and tube-forming capacity observed in control cells was suppressed in experimental diabetes in parallel with reduced NOX4 expression and rescued by plasmid NOX4OE. As direct evidence of clinical relevance, CB-ECFCs from gestational diabetic donors showed reduced angiogenic potential associated with attenuated NOX4, eNOS activity and downregulation of key vasoreparative signalling. Furthermore, NOX4OE rescued angiogenic function in chronically diabetic CB-ECFCs via modulation of downstream signalling involving both direct and indirect enhancement of pro-angiogenic protein expression (endoglin/SERPINE1/E2F1) linked to reduced p53 phosphorylation.

conclusionsTaken together, these data indicate for the first time that reduced NOX4 expression plays a pivotal role in CB-ECFC angiogenic dysfunction linked with diabetes whilst highlighting NOX4-dependent signalling as a potential target to protect and augment their intrinsic vasoreparative capacity towards addressing current translational barriers.

Indexed as

Diabetes Mellitus, ExperimentalEndothelial Progenitor CellsNADPH Oxidase 4Neovascularization, PhysiologicCell MovementCells, CulturedDiabetes, GestationalFemaleHumansReactive Oxygen SpeciesSignal TransductionNADPH Oxidase 4NOX4 protein, humanReactive Oxygen SpeciesAngiogenesisDiabetes cardiovascular diseasesEndothelial progenitor cellsNADPH oxidase 4

Identifiers

PMID40457435
PMCPMC12131569

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.